NEW YORK, Nov. 7, 2022 /PRNewswire/ — According to the latest market research report published by P&S Intelligence, in 2021, the advanced wound care market was worth around $8.05 billion, and it is predicted to advance at a 5.8% CAGR from 2021 to 2030, to hit $13.4 billion. This is because of the surging count of injuries due to surgery and other reasons and the increasing cases of diabetes.
Advanced Wound Dressings Are Most Commonly Used
Advanced wound dressing accounts for the largest share, owing to the growing incidence of healthcare-related infections and surging awareness among the population of their effects. Moreover, the growing incidence of pressure ulcers, venous ulcers, and diabetic ulcers is escalating the growth of the category.
Growing Demand for Advanced Care for Acute Wounds
The acute wounds category holds an over 55% share of the market, owing to the snowballing incidence of road accidents. Additionally, the number of non-fatal injuries requiring appropriate medical care has increased recently around the world.
Further, because of the increasing prevalence of venous pressure ulcers and diabetic foot ulcers, the chronic wounds category is projected to grow at a higher CAGR, of around 5.9%, in the coming years. For instance, more than 2 million diabetics have foot ulcers in the U.S. annually.
Get the sample pages of this report: https://www.psmarketresearch.com/market-analysis/advanced-wound-care-market/report-sample
Patients Prefer Hospitals due to Their Demand for Comprehensive Care
With a market share of over 40%, hospitals led the market in 2021. This was due to the comprehensive care that patients with wounds receive from trained personnel in inpatient hospital facilities.
Moreover, due to the trend of home isolation brought on by the COVID-19 pandemic and surge in the senior population, the home healthcare category is predicted to register the highest rate of growth, of more than 6%, in the future.
North America Had Highest Need for Advanced Wound Care
In the past, North America held an over 43% share in the global advanced wound care market, driven by the growing elderly population and rising rates of obesity, diabetes, burns, and motor vehicle accidents.
Half way across earth, the aging population, growing diabetes prevalence, and rising burn cases are set to drive the product demand in APAC at the highest CAGR. In addition, the increase in the chronic illness prevalence brought on by the changing lifestyles is driving this growth in the region.
Browse detailed report on Advanced Wound Care Market Size, Share and Growth Analysis 2022-2030
Demand for Combination Dressings Is Snowballing
The qualities of many dressings are combined to create a combination dressing, which performs better than the separate products. For diabetic foot ulcers, infected injuries, and pressure ulcers, silver–alginate, silver–collagen, and collagen–hydrochloride combination dressings are frequently utilized.
Advanced Wound Care Market Report Coverage
By Type
Advanced Wound Dressing
Wound Therapy Device
Active Wound Care Products
By Application
Acute Wounds
Chronic Wounds
By End User
Hospitals
Clinics
Home Healthcare
Regional Analysis
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Browse More Reports Published by P&S
Global Wound Care Market Size, Share, and Growth Analysis, 2030
Colombia Wound Care Market Size, Share, and Growth Analysis, 2030
Hong Kong Wound Care Market Size, Share, and Growth Analysis, 2030
Global Disposable Plastic Blood Bags Market Size, Share, and Growth Analysis, 2030
About P&S Intelligence
P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies.
Contact:
Prajneesh Kumar
P&S Intelligence
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Follow Us: LinkedIn Twitter
Logo: https://mma.prnewswire.com/media/1224988/P_and_S_Intelligence_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/advanced-wound-care-market-to-surpass-13-4-billion-value-by-2030-ps-intelligence-301670116.html
SOURCE P&S Intelligence
Medtronic plc (NYSE: MDT) announced the six-month results from the full cohort of the SPYRAL HTN-ON MED trial. Subjects in the Symplicity Spyral Renal Denervation (RDN) System had a statistically significant and clinically meaningful reduction in office-based systolic blood pressure (OSBP), a key secondary endpoint, compared to the sham control group. However, in the primary endpoint, RDN did not demonstrate a statistically significant reduction in 24-hour ambulatory systolic blood pressure (ABP
Axsome Therapeutics (NASDAQ: AXSM), a central nervous system disorder specialist, is having a good day today. Although Axsome's management spent quite a bit of time discussing the commercial prospects of the excessive daytime sleepiness medication Sunosi during this latest earnings call, Wall Street and the company's shareholders alike are primarily interested in the ongoing commercial launch of Auvelity. Auvelity, which was approved by the Food and Drug Administration earlier this year as a novel treatment for major depressive disorder, became commercially available on Oct. 20.
Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.
Gilead Sciences (NASDAQ: GILD) saw its shares rise 27.20% in October, according to data from S&P Global Intelligence. The biotech stock ended September at $61.69. Gilead, a biopharmaceutical company that focuses on oncology and HIV therapies, showed it has a strong future even as sales of its COVID-19 therapy, Veklury (remdesivir), have begun to ebb.
Thank you for holding, and welcome, everyone, to the Agenus third quarter 2022 financial results call. Now, I'd like to turn the call over to Garo to highlight our progress and speak to our outlook for the remainder of the year.
Medtronic’s Symplicity system, which stimulates nerves near the kidneys to treat hypertension, yielded disappointing results in 2014. It did better the second time — though it failed to prove itself significantly better than drugs.
CRISPR Therapeutics AG (NASDAQ: CRSP), a gene-editing clinical-stage biotech company, saw its shares fall 19.9% in November, according to data from S&P Global Intelligence. It opened October at $66.02 and then fell steadily throughout the month, dropping to a monthly low of $48.49 on Oct. 24. The stock concluded the month at $52.34 and is down more than 33% so far this year, with a 52-week low of $42.51 and a 52-week high of $95.
Amazon has a pretty strong track record when it comes to successfully branching out into new areas where competition is fierce. The company has built its Amazon Web Services (AWS) cloud platform into a global powerhouse for computer storage solutions. Amazon Prime Studios has become one of the most powerful Hollywood studios just a few years into its existence.
The healthcare industry is constantly growing, changing, and evolving, which will continue in the coming years. Among the leaders in these segments of the industry are HCA Healthcare (NYSE: HCA) and Johnson & Johnson (NYSE: JNJ). HCA Healthcare is a leading hospital chain company with operations throughout the U.S. Although there is plenty of competition, the company has grown its market share in the past decade and again during the troubled pandemic years.
Shares of Veru (NASDAQ: VERU) were skyrocketing 40.7% higher at 11:17 a.m. ET on Monday. The huge gain came after the U.S. Food and Drug Administration (FDA) released a briefing document related to Veru's Emergency Use Authorization (EUA) request for the COVID-19 drug sabizabulin. The FDA's Pulmonary-Allergy Drugs Advisory Committee Meeting to review this EUA request is scheduled for Nov. 9, 2022.
Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.
The company has applied for FDA approval of Symplicity Spyral, an experimental device used to perform a minimally invasive treatment procedure.
Organon (NYSE: OGN), a global women's health company, is announcing the launch and product availability of Aybintio®, a biosimilar of Avastin®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recur
Staff reviewers at the U.S. Food and Drug Administration on Monday identified several uncertainties around Veru Inc's data for its experimental COVID-19 drug but did not raise any new concerns, sending its shares surging 52%. The reviewers also did not offer any strong argument against the emergency use authorization (EUA) even as they flagged the small size of the trial that showed the drug reduced death rates, analysts said. The data did not help clearly identify a relevant patient population and the high rate of deaths in a placebo group in the trial may raise questions about the results, the reviewers said.
Is Pfizer stock a buy or a sell as it aims to gain the first approval for a maternal SRV shot? Is PFE stock a buy or a sell right now?
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the presentation of new data from the Phase 3 RAPID clinical trial of etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting. The presentation, titled "Self-administered Etripamil for Termination of Spontaneous Paroxysmal
Is Merck stock a buy after the company notched a third-quarter beat and raised guidance for 2022? Is MRK stock a buy now?
The "Little House on the Prairie" star got candid with her social media followers about what it takes to prep for a colonoscopy procedure.
Wondering if you are experiencing 'bigorexia' symptoms? Here's what to know about bigorexia, including disorder warning signs, treatment and how to cope.
Courtesy of Laura LyonsWhen it comes to living with long COVID, there is no bright side, no good part, no silver lining. Trust me. I’ve been battling this chronic illness since early 2020, when people still called it “Corona” and everyone was making Instagram memes about a beer company.When COVID-19 first arrived on America’s unprepared shores, I was a New York City-based 31-year-old comedian with a promising career ahead of me. Then, in March 2020, I developed symptoms that at first weren’t con
Diabeets
08/11/2022